GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International, Inc. (FRA:HIY1) » Definitions » ROA %

Heartware International, (FRA:HIY1) ROA % : -10.07% (As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Heartware International, ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Heartware International,'s annualized Net Income for the quarter that ended in Jun. 2016 was €-38.7 Mil. Heartware International,'s average Total Assets over the quarter that ended in Jun. 2016 was €384.7 Mil. Therefore, Heartware International,'s annualized ROA % for the quarter that ended in Jun. 2016 was -10.07%.

The historical rank and industry rank for Heartware International,'s ROA % or its related term are showing as below:

FRA:HIY1' s ROA % Range Over the Past 10 Years
Min: -86.09   Med: -30.14   Max: -4.54
Current: -12.88

During the past 10 years, Heartware International,'s highest ROA % was -4.54%. The lowest was -86.09%. And the median was -30.14%.

FRA:HIY1's ROA % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -2.11 vs FRA:HIY1: -12.88

Heartware International, ROA % Historical Data

The historical data trend for Heartware International,'s ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International, ROA % Chart

Heartware International, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.72 -39.28 -18.38 -4.78 -17.50

Heartware International, Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.83 -24.45 -0.79 -15.53 -10.07

Competitive Comparison of Heartware International,'s ROA %

For the Medical Devices subindustry, Heartware International,'s ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heartware International,'s ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heartware International,'s ROA % distribution charts can be found below:

* The bar in red indicates where Heartware International,'s ROA % falls into.



Heartware International, ROA % Calculation

Heartware International,'s annualized ROA % for the fiscal year that ended in Dec. 2015 is calculated as:

ROA %=Net Income (A: Dec. 2015 )/( (Total Assets (A: Dec. 2014 )+Total Assets (A: Dec. 2015 ))/ count )
=-66.812/( (343.712+420.055)/ 2 )
=-66.812/381.8835
=-17.50 %

Heartware International,'s annualized ROA % for the quarter that ended in Jun. 2016 is calculated as:

ROA %=Net Income (Q: Jun. 2016 )/( (Total Assets (Q: Mar. 2016 )+Total Assets (Q: Jun. 2016 ))/ count )
=-38.744/( (387.32+382.141)/ 2 )
=-38.744/384.7305
=-10.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2016) net income data. ROA % is displayed in the 30-year financial page.


Heartware International,  (FRA:HIY1) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2016 )
=Net Income/Total Assets
=-38.744/384.7305
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-38.744 / 244.644)*(244.644 / 384.7305)
=Net Margin %*Asset Turnover
=-15.84 %*0.6359
=-10.07 %

Note: The Net Income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Heartware International, ROA % Related Terms

Thank you for viewing the detailed overview of Heartware International,'s ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Heartware International, (FRA:HIY1) Business Description

Traded in Other Exchanges
N/A
Address
Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.

Heartware International, (FRA:HIY1) Headlines

No Headlines